Articles tagged with Cancer Patients
A Phase I study of an experimental antibody produced at St. Jude Children's Research Hospital found tumors shrank or disappeared in some patients with advanced neuroblastoma, and disease progression was temporarily halted in 15 children.
Researchers at Wake Forest Baptist Medical Center have successfully treated patients with recurrent lung cancers using a second course of radiation therapy, achieving a cure rate of over 70%. The innovative treatment approach uses precise targeting and high doses to knock the cancer back, offering new hope for these patients.
A Kaiser Permanente study found that radiation treatment significantly reduced the risk of Merkel cell carcinoma recurrence, with no impact on survival rates. The study's results also showed associations between immunosuppression and advanced tumors, as well as lymph node evaluation, and worse survival outcomes.
The GW Cancer Institute has received a $100,000 grant from the Avon Foundation to support a patient navigator. The patient navigator will help remove barriers and coordinate access to care for over 1,000 patients with breast cancer in the Washington D.C. area.
Researchers used molecular tumor boards to evaluate 34 patients with advanced cancer, identifying 74 genes and 123 aberrations involved in cancer growth. The approach showed promise in tailoring personalized treatment plans for patients who have exhausted standard therapies.
A review of 47 studies involving over 15,000 patients found that liver cancer screening using ultrasound scans and blood tests significantly improved three-year survival rates for people with cirrhosis. Cirrhosis patients who received screening were more likely to receive curative treatment rather than palliative care.
A phase III clinical trial shows that non-invasive magnetic resonance guided focused ultrasound treatment relieves pain and improves function for most patients with bone metastases. Patients responded well to treatment, with 64 percent experiencing either no pain or a significant reduction in their pain within several days of treatment.
A study published in Journal of Clinical Oncology found low transmission rates among long-term partners of patients with oral HPV infection. The prevalence of oral HPV among partners was comparable to the general population, confirming that couples do not need to change their intimacy due to cancer diagnosis.
Dartmouth researchers found tweens who participate in coached team sports are less likely to try smoking. Participating in other clubs was also associated with lower risk of trying drinking.
Microfluidic technology reveals potential biomarker for early pancreatic cancer, capturing circulating pancreas cells in 33% of patients with early lesions. The detection may indicate an early sign of cancer, and a clinical trial is underway to predict patient risk.
Researchers discovered that tumors with specific immunogenic mutations can activate a protective immune response, leading to higher overall survival rates. The study's findings support personalized cancer immunotherapy approaches and the use of tumor-specific mutations in creating targeted vaccines.
A study found that vitamin D levels are linked to better outcomes in several types of cancer. Patients with higher vitamin D levels tend to have better survival rates and remain in remission longer than those who are deficient.
Dartmouth has been awarded a grant to serve as a Lead Academic Participating Site in the National Clinical Trials Network, aiming to streamline clinical trial operations and improve access to new treatments. The network's goals include faster trial design, optimal use of scientific innovations, and expanded patient participation.
Researchers discovered that PTEN mutations contribute to tumorigenesis by regulating different aspects of PTEN biology, and targeting Akt's pathway may be an effective treatment strategy for patients with PTEN mutations. The findings suggest that personalized cancer medicine is urgently needed.
The American Society for Radiation Oncology (ASTRO) has issued a new guideline detailing the use of adjuvant radiation therapy in treating endometrial cancer. The guideline recommends postoperative external beam radiation for patients with early-stage disease, and vaginal cuff brachytherapy for those at high risk of vaginal recurrence.
Researchers at Ohio State University found that microRNA-3151 promotes AML-cell growth and survival by blocking tumor-suppressor gene TP53. High expression of miR-3151 is associated with a bad prognosis, while inhibition with the drug bortezomib offers a possible therapy.
Celldex Therapeutics' Phase 1 study of CDX-1401 demonstrates robust antibody and T cell responses, with evidence of clinical benefit in patients with very advanced cancers. The vaccine induces durable humoral and cellular immunity, with stable disease observed in a significant proportion of patients.
A new blood test, cMethDNA assay, has been developed to detect advanced breast cancer and monitor its response to treatment with high accuracy. The test detected cancer DNA in the blood of patients with metastatic breast cancers up to 95% of the time, making it a promising tool for early detection and treatment monitoring.
Clinical trials show chemotherapy before surgery improves muscle-invasive bladder cancer survival. Chemotherapy after surgery also increases survival rates, with a significant improvement over time.
A new study finds that microRNA 135b drives the growth of bowel cancers and is a vital 'worker' for several important cancer genes. Testing levels of this molecule could identify patients with aggressive disease, while drugs targeting it may prevent tumour growth and reduce resistance.
A study of 305 patients undergoing radiation treatment found that playing an active role in their treatment decisions improved patient satisfaction. Patients who experienced shared decision making or perceived control over their treatments were more satisfied and reported lower levels of anxiety, depression, and fatigue.
A study by UT Southwestern Medical Center found that popular web information on colorectal cancer screening materials are written beyond the recommended sixth-grade reading level and fail to address key risks and barriers. Only half of the sites discussed colorectal cancer risk in the general population, while only a quarter specifical...
Researchers found a genetic connection between APOBEC family of genes and breast cancer development. The study linked the genes to mutations present in half of all cancer types, supporting their role in cancer-causing processes.
UT Southwestern Medical Center received a $3.24 million grant from the National Cancer Institute to bolster its clinical cancer research and provide patients with access to cancer research trials. The center will expand its offerings of experimental cancer treatments, more than doubling adult participation in clinical trials.
Researchers at Dartmouth's Geisel School of Medicine identified a potential therapeutic target for glioblastoma multiforme, a deadly form of brain cancer. The study found that STK17A protein is induced in response to DNA damage and is correlated with poorer outcomes.
A research team led by Ellis L. Reinherz and Robert I. Haddad will focus on developing new vaccines and immunotherapeutic approaches to improve outcomes for patients with HPV-driven cancers who have relapsed after initial therapy. The grant aims to provide a novel approach to treating this population.
The Bezos family's $20 million donation will support the development of novel cancer immunotherapies for various solid tumor cancers. The gift promises to save lives by expanding the use of immunotherapy to treat a range of deadly cancers.
Researchers at Dartmouth found that disrupting VISTA, a protein preventing overreaction, enhanced the immune system. This discovery may lead to new cancer treatments using the immune system.
The Farrah Fawcett Foundation is supporting a new $1.2 million research team to develop vaccines and immunotherapies for HPV-driven cancers, which currently have few therapeutic options. The team aims to identify tumor targets, activate specific immune cells, and deploy them at the tumor site for selective destruction of cancer.
The Mayo Clinic uses frozen section analysis during breast cancer lumpectomies, sparing patients the need for repeat surgeries in 96% of cases. This technique significantly lowers the 30-day reoperation rate from 13.2% nationally to 3.6% at Mayo.
The SU2C Phillip A. Sharp Innovation in Collaboration Awards aim to foster synergistic and innovative collaborations among SU2C scientists. The inaugural awards will support five grants totaling $950,000, focusing on projects that enhance the SU2C mission to accelerate cancer treatment development.
Researchers at Stanford Medicine have developed a highly sensitive and specific blood test that can accurately identify stage-1 lung cancer patients and detect rare cancer mutations. The CAPP-Seq technique analyzes tumor DNA in the blood to provide non-invasive monitoring of cancer progression and treatment responses.
Patients with HPV+ throat cancer have good prognosis, but tumors elsewhere in the head and neck have no prognostic effect of being HPV+, researchers found. HPV status has significant impact on tumour control, survival, and death from any cause for oropharyngeal cancers.
In mice, obese fathers pass on their weight and gene expression changes to their daughters, increasing the risk of obesity and breast cancer later in life. This study provides evidence for a potential paternal link to cancer risk, challenging traditional research focus on maternal influences.
A clinical trial found that genetic screening can help doctors customize treatments for patients with advanced melanoma, reducing cancer recurrence risk by 63%. The study used ipilimumab therapy and identified biomarker signatures to tailor treatment plans.
A new study found that ovarian cancer patients' disease-free survival rates significantly improved over time, particularly among those with poorer initial prognoses. The research suggests that considering the time elapsed since remission may provide a more accurate prognosis and inform better follow-up care decisions.
Researchers at UPCI discovered that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen, indicating potential targets for drug therapy. The study suggests a unique signaling pathway regulated by estrogen in lobular carcinoma cells may be exploited in future clinical trials.
Physician Emil J Freireich and scientist Jim Allison have been elected as fellows of the American Association for Cancer Research Academy, known for their contributions to cancer treatment and immunotherapy. Their work has driven significant innovation and progress against cancer, leading to improved survival rates for patients.
A comprehensive review suggests that mammography screening benefits are often exaggerated while harms are understated. The study's findings emphasize the need for individualized approach to breast cancer screening based on clinical factors and personal preferences.
A new study found that certain genetic variants, such as ALDH2 and VCAM1, can predict bladder cancer recurrence in patients. These variants can help identify high-risk patients who require more frequent screenings and aggressive treatment, improving quality of life for all bladder cancer patients.
Researchers estimate that up to 100% of lung cancer patients experience sexual dysfunction, which can persist after treatment. Experts call for open discussions and specialized help from healthcare professionals to address these issues.
Researchers developed a predictive tool that analyzes gene expression changes to predict patient survival. The tool, based on mouse studies, has shown promise in predicting treatment risk for early-stage breast cancer and certain lung cancers.
Scientists have developed a method to freeze testicular tissue in boys undergoing chemotherapy and radiation treatments for cancer, allowing them to preserve fertility. The study found that cancer cells were eliminated during the process of reproducing sperm-producing stem cells, making this option safe for future use.
Researchers discovered that breast cancer tumors can hijack patients' repressive gene regulatory machinery, permanently blocking cancer-killing genes. This allows the cancer to continue growing despite treatment with aromatase inhibitors, which block estrogen synthesis.
A new study identified genetic variants associated with increased risk of bladder cancer recurrence. Inheriting certain DNA sequences may affect a patient's prognosis, allowing physicians to tailor surveillance and treatment plans.
A study at Dana-Farber Cancer Institute found wide variation in oncologists' attitudes towards offering cancer gene testing, with those having high genomic confidence more likely to prescribe the test. The survey revealed that 42% of doctors approved telling patients about uncertain test results, highlighting concerns about delivering ...
Researchers found that people with a rare chromosome abnormality have a 2,700-fold increased risk of a rare childhood leukemia. The fusion of chromosomes 15 and 21 led to chromothripsis, which shattered the chromosome and created an optimised genome for leukaemia.
A groundbreaking study led by TGen has identified a genetic mutation in the SMARCA4 gene as the primary driver of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a rare and aggressive form of ovarian cancer. This discovery holds promise for developing targeted therapies and improving diagnosis.
New research by USC Norris Comprehensive Cancer Center scientists suggests that elevated CTC counts after chemotherapy indicate a higher risk of death, while reduced CTCs cut the risk in half. This study demonstrates CTCs as an important biomarker for cancer research and treatment.
A new study found that CDK4 inhibitors may promote the development and progression of certain B-cell lymphomas driven by the MYC oncogene. Inhibiting CDK4 leads to genetic instability and genomic alterations associated with cancer growth.
A study by researchers from Huntsman Cancer Institute found that about 6 percent of colorectal cancers are missed during colonoscopies, particularly in patients over 65 and those with a family history of the disease. The cancers may develop rapidly after the procedure or be overlooked due to factors like polyp size or location.
Cologuard detects precancer and cancer with high sensitivity rates, surpassing existing non-invasive tests, offering a user-friendly approach to expand screening effectiveness and curb colorectal cancer rates. The test's accuracy has transformed how we think about colorectal cancer screening.
Researchers at TGen identified the ALK-EML4 gene fusion as the genetic driver of an aggressive type of thyroid cancer. The study's findings suggest that this fusion can be targeted with existing drug crizotinib, offering a new treatment option for patients with radioiodine-resistant aggressive papillary thyroid cancer.
Using big data analytics, researchers can predict the type of breast, lung, or oropharyngeal cancers with high accuracy. This technology may enable doctors to use MRI scans to diagnose more aggressive cancers earlier, leading to faster treatment options and improved patient outcomes.
The Ohio State University has partnered with MedVax Technologies Inc. to develop a cancer peptide vaccine technology for the treatment and prevention of several types of cancer. The partnership aims to bring this groundbreaking technology into clinical trials in the near future, with the goal of improving patient outcomes.
Researchers at UC Davis hope to prove that mobile health technology improves cancer patient care, quality, and reduces costs. The project uses a unique social networking tool to connect patients with their nurse coordinators, family, caregivers, and clinicians.
Research published in Diabetologia found that cancer patients with diabetes have a higher risk of early death due to the combination of diabetes and cancer. Patients treated with insulin had the highest mortality rate, while those with oral hypoglycaemic agents or no treatment showed lower risks
A new national analysis of trends and outcomes reveals that pancreatic cancer surgery remains under-utilized for patients with the deadly disease. Researchers identified factors associated with not receiving surgery in patients with localized pancreatic cancer, including age, race, and location.
A phase I trial found a complete response for 14 months to everolimus and pazopanib in a patient with advanced bladder cancer and rare mTOR genetic mutations. Genomic profiling revealed two alterations that activated the mTOR-mediated cell signaling pathway, rendering the cancer sensitive to the mTOR inhibitor.
Researchers identify two rare mutations in the mTOR gene associated with a complete response to everolimus and pazopanib, leading to improved treatment options for patients. The study provides new insights into personalized medicine and targeted therapies for bladder cancer.